PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of frontoncoLink to Publisher's site
 
Front Oncol. 2017; 7: 49.
Published online 2017 April 4. doi:  10.3389/fonc.2017.00049
PMCID: PMC5378717

Mammalian SWI/SNF Enzymes and the Epigenetics of Tumor Cell Metabolic Reprogramming

Abstract

Tumor cells reprogram their metabolism to survive and grow in a challenging microenvironment. Some of this reprogramming is performed by epigenetic mechanisms. Epigenetics is in turn affected by metabolism; chromatin modifying enzymes are dependent on substrates that are also key metabolic intermediates. We have shown that the chromatin remodeling enzyme Brahma-related gene 1 (BRG1), an epigenetic regulator, is necessary for rapid breast cancer cell proliferation. The mechanism for this requirement is the BRG1-dependent transcription of key lipogenic enzymes and regulators. Reduction in lipid synthesis lowers proliferation rates, which can be restored by palmitate supplementation. This work has established BRG1 as an attractive target for breast cancer therapy. Unlike genetic alterations, epigenetic mechanisms are reversible, promising gentler therapies without permanent off-target effects at distant sites.

Keywords: SMARCA4, breast cancer, SWI/SNF, fatty acid synthesis pathway, chromatin remodeling, epigenetic regulation, cancer metabolism

Tumor cells reprogram their metabolism to support growth in their unique and challenging microenvironment, a hypoxic environment with inadequate blood supply for normal nutrient replenishment. As first observed by Otto Warburg (1, 2), tumor cells develop a glycolytic metabolism where energy is derived primarily from nutrient catabolism to lactate and not from the mitochondrial Krebs cycle where cells in normal tissue derive most of their energy. Although adaptive to a hypoxic tumor microenvironment, this preference for glycolysis persists even when oxygen is abundant. The nutrient fuel for glycolysis is glucose, but tumor cells also become “addicted” to the normally non-essential amino acid glutamine (3), as first observed in cultured cells by Harry Eagle (4). Glutamine can serve as a carbon and nitrogen source for amino acid synthesis and can fuel the residual Krebs cycle after conversion to glutamate and then α-ketoglutarate. After a period of neglect, cancer metabolism is now recognized as central to the cancer phenotype and as an important target for the development of therapies (5).

Regulation of Metabolism

Cells carefully regulate their metabolism with nested levels of controls (6). First, levels of circulating molecules that serve as feedstock for metabolic pathways change with diet. These include plasma-free fatty acids and amino acids that increase after a meal (7) or plasma ketone bodies and free fatty acids that increase after a prolonged fast (8, 9). Second, allosteric regulation of metabolic enzymes changes flux rates through metabolic pathways in response to concentrations of substrates or products (1012). Third, there is regulation by hormones (13), often through posttranslational modification of metabolic enzymes. For example, glycogen deposition or depletion is regulated by a protein kinase cascade-modifying glycogen synthase and glycogen phosphorylase downstream of insulin or glucagon (14, 15). AMP-activated Kinase (AMPK) is a master regulator of metabolism that can sense cellular energy status and respond by switching on and off pathways to achieve energy homeostasis (16, 17). AMPK is activated in response to cellular ATP depletion, which can result from low glucose levels, hypoxia, and heat shock. Upon activation, AMPK upregulates pathways replenishing ATP, including fatty acid β-oxidation and autophagy, and downregulates ATP-consuming processes, including lipid synthesis and protein synthesis.

The protein kinase mTOR (mechanistic target of rapamycin) (18, 19) is the core Ser/Thr protein kinase in two signal transduction complexes, mTORC1 and mTORC2. mTORC1 is a master growth regulator that senses and integrates diverse signals, including levels of growth factors, amino acids, other metabolites, and cellular stress. mTORC2 activates the cell signaling Ser/Thr protein kinase AKT, promotes cellular survival, regulates cytoskeletal dynamics, and regulates growth via SGK1 phosphorylation. mTOR complexes promote cell growth through regulation of anabolic and catabolic metabolic processes by multiple mechanisms, as well as through control of cell proliferation. An altered interplay of all of these mechanisms participates in the progressive reprogramming of metabolism with tumor progression.

Transcriptional Regulation of Metabolism

Metabolic pathways can also be regulated by transcriptional mechanisms increasing or decreasing levels of enzymes. Take the example of lipid metabolism. The Sterol Regulatory Element Binding Protein (SREBP) transcription factors are the master regulators that control the expression of nearly all lipogenic enzymes. The mTORC1 complex regulates lipid synthesis (20) through SREBP by multiple mechanisms. In response to cellular signaling, mTORC1 regulates SREBP processing through S6K and increases SREBP nuclear accumulation through Lipin 1, a phosphatidic acid phosphatase that is also a transcriptional coactivator (2125). mTORC1 phosphorylates Lipin1, preventing its translocation into the nucleus where it can inhibit SREBP1/2-dependent transcription (24). mTORC1 also increases the activity and expression of peroxisome proliferator-activated receptor γ (PPARγ), another transcriptional regulator of lipogenic genes (26, 27). By these mechanisms, mTORC1 increases the transcription of lipogenic genes, including key enzymes in fatty acid synthesis, such as acetyl CoA carboxylase (ACC), ATP citrate lyase (ACLY), and fatty acid synthase (FASN). As we shall discuss, we have shown Lipin1 and each of these enzymes involved in fatty acid synthesis to be transcriptionally regulated by Brahma-related gene 1 (BRG1), a chromatin remodeling enzyme (28).

Cancer Epigenetics

Epigenetic mechanisms control heritable phenotypes without changes in DNA sequence, often changing chromatin structure by modulating DNA methylation, the posttranslational modification of histones and non-histone chromatin associated proteins, and the regulation of ATP-dependent chromatin remodeling enzymes that control genome accessibility (29). Epigenetic mechanisms regulate normal development and maintain tissue-specific gene expression patterns while their disruption can cause altered gene function and contribute to malignant cellular transformation. The initiation and progression of cancer has been seen as a genetic disease, but we now realize that epigenetic abnormalities contribute to the development of cancer. Cancer cells often have altered levels or activities of epigenetic regulatory proteins with consequences including altered chromatin structure and altered regulation of gene expression (30, 31). These are so common and numerous that global changes in the epigenetic landscape are now considered a hallmark of cancer (5).

The Role of BRG1 in Cancer Epigenetics is Context Dependent

Chromatin structure presents a barrier to transcription factors and polymerases accessing DNA. Several multiprotein complexes alter chromatin structure using the energy derived from ATP-hydrolysis (3234), including the mammalian SWI/SNF family of chromatin modifiers, which are large, multisubunit enzymes that contain one of two closely related ATPases called BRM or BRG1 (3537). SWI/SNF complexes containing either catalytic subunit alter nucleosome structure and facilitate binding of transcription factors to nucleosomal DNA in an ATP-dependent manner (38, 39). Subunits of the mammalian SWI/SNF complexes are important for gene activation and repression, development and differentiation, recombination and repair, cell cycle control, and tumorigenesis (4043). For example, the SNF5 (INI1) subunit is required for embryonic development and functions as a tumor suppressor (4446).

Brahma-related gene 1 (BRG1) function in cancer is context dependent. BRG1 is mutated in lung and other cancers, where it may function as a tumor suppressor (30, 47). Cancers that have lost the SWI/SNF INI1 subunit require BRG1 (48), suggesting that targeting BRG1 may be therapeutic for these tumors. Similarly, targeting BRM might be an effective strategy for targeting BRG1-deficient tumors (49, 50). As we and others have shown, BRG1 is upregulated but rarely mutated in primary breast and prostate tumors, in melanoma and neuroblastoma, and in pancreatic, gastric, and colorectal carcinomas (5160). Mice heterozygous for Brg1 develop mammary tumors (61, 62). However, conditional knockout of Brg1 in mammary gland does not cause mammary tumors (63). Genome sequencing of more than 500 primary breast cancers showed none with mutations in BRG1 (64). The evidence suggests that BRG1 can be a driver of cancer as well as a tumor suppressor.

Fatty Acid Metabolism and Cancer

In tissues with high rates of lipogenesis such as liver, lactating mammary gland, and adipose tissue, the fatty acid synthesis pathway has three principal functions: storage of excess energy as fat, synthesis of lipids from carbohydrate or protein precursors when dietary lipids are scarce, and synthesis of milk fats during lactation. Most normal cells in other tissues do not synthesize fatty acids de novo but preferentially use circulating lipids. However, upregulation of both lipogenic genes and overall lipogenesis are observed widely in tumors in those non-lipogenic tissues (65). Depending on the tumor type, tumor cells synthesize up to 95% of saturated and mono-unsaturated fatty acids de novo from acetyl CoA despite a sufficient exogenous supply of fatty acids (66). Lipogenic enzymes, such as FASN, ACC, and ACLY that are required for fatty acid biosynthesis, and SREBP1, the master regulator of lipogenic gene expression, are overexpressed in many cancers, including breast (6770). FASN is a key enzyme involved in energy storage from excess carbohydrates to fat in liver and adipose tissue, during lactation in breast, and in support of reproduction in endometrium and decidua. But FASN expression during these processes is strictly regulated by nutrition and hormonal levels. In contrast, FASN is highly expressed in many cancer and precancerous lesions. The expression of FASN is independent of nutrition, in many cancers, as well as independent of hormonal regulation. Whereas various tumor types have elevated endogenous fatty acid biosynthesis irrespective of extracellular lipid availability, most normal cells, even those proliferating rapidly, preferentially use exogenous lipids for synthesis of new structural lipids (65, 71).

The activation of the de novo fatty acid synthesis pathway is not only observed in tumors but also may be required for malignant progression (65, 72, 73). For example, elevated levels of FASN, the enzyme catalyzing the synthesis of palmitate and thereby required for long chain and unsaturated fatty acid synthesis, are correlated with poor prognosis in breast cancer patients (65, 72). Increases in FASN activity and expression are observed early in cancer development and correlate with cancer progression, while high FASN levels correlate with more aggressive malignant phenotypes (65). Inhibiting key enzymes involved in fatty acid synthesis, including FASN, ACC, and ACLY, with small molecules or knockdowns reduces cell proliferation, induces the apoptosis of cancer cells, and decreases the growth of human tumors grown as mouse xenografts (65, 71, 7477).

BRG1 is Necessary for Fatty Acid Biosynthesis in Support of Proliferation in Breast Cancer

We first reported that the alternative SWI/SNF chromatin remodeling enzyme ATPases BRG1 and BRM are required for proliferation of breast cancer cells (59). Western blots of biopsies showed that BRG1 protein levels were higher in tumor than in normal tissue. Analysis of TCGA Breast Cancer patient data revealed an approximate twofold increase in BRG1 mRNA levels (64) and in BRG1 protein levels (78) in tumors compared to normal tissue across all subtypes. These are not well-controlled comparisons because of the great heterogeneity in normal tissue cell types. More convincingly, immunohistochemistry confirmed that the BRG1 and BRM proteins are greatly overexpressed in most primary breast cancers independent of receptor status (55, 59). BRG1 staining was rarely observed in the normal ductal epithelial cells from which most breast tumors derive but was seen in normal myoepithelial cells. However, in tumors BRG1 staining was observed in almost every cell. Because of the heterogeneity of breast cancer subtypes our further experimental work focused on triple-negative breast cancer, the most aggressive and deadly type.

Knockdown of either ATPase in triple-negative breast cancer cell lines reduced cell proliferation in vitro and tumor formation in xenografts. An extended cell cycle progression time was observed without apoptosis, without senescence, or without alterations in migration or attachment. Combined knockdown of BRM and BRG1 produced additive effects, suggesting that these enzymes function, at least in part, through independent mechanisms. Knockout of BRG1 or BRM using CRISPR/Cas9 technology caused cell death. Our work supports the novel idea that overexpression of BRG1 and BRM is common in breast cancer and that BRG1 and BRM are required for breast cancer cell proliferation and survival. These results are in direct contrast to other tumors where BRG1 acts as a tumor suppressor (79). For example, it is mutated in lung and other cancers. We and others have now shown that BRG1 is upregulated but rarely mutated in primary breast and prostate tumors, in melanoma and neuroblastoma, and in pancreatic, gastric, and colorectal carcinomas (5160, 80).

When we began our studies, it was expected that BRG1 was a weak tumor suppressor in mammary gland because about 10% of Brg1+/− mice eventually developed mammary tumors (61, 62) and because there were functional interactions between BRG1 and cell cycle regulatory proteins, including RB and p53 (30, 42, 81). This tentative identification of BRG1 as a mammary tumor suppressor was challenged by our work (59) and by others (55). The conditional knockout of Brg1 in the mouse mammary gland did not cause mammary tumors (63). We observed that fewer than 2% of BRG1 sequences in the TCGA database contained mutations. Breast cancer is not alone in this requirement for BRG1. BRG1 is also required for the proliferation of HeLa cells and mouse fibroblasts (82, 83).

What is the mechanism for the BRG1 requirement for breast cancer cell proliferation? We discovered that BRG1 promotes breast cancer by reprogramming lipid synthesis (28) as shown in Figure Figure1.1. BRG1 knockdown reduced the rate of chloroform/methanol extractable lipid synthesis by 35% while glucose uptake remained unchanged. mRNA and protein levels for ACC, ACLY, and FASN, the key enzymes in de novo fatty acid synthesis, were all significantly decreased in BRG1 knockdown cells as were other important proteins performing or regulating lipid synthesis such as Lipin1. BRG1 bound to the promoters of all of these genes, and the promoter binding was diminished in BRG1 knockdown cells, evidence of direct BRG1 transcriptional control. Treatment with either an ACC inhibitor or a FASN inhibitor decreased cell number, and BRG1 knockdown cells showed increased sensitivity to these inhibitors. Remarkably, addition of exogenous palmitate, the key intermediate in fatty acid synthesis, completely rescued proliferation. Our work supports a mechanism in which BRG1 transcriptionally promotes de novo lipid synthesis, which is necessary for maintaining high rates of proliferation. In these cells, exogenous palmitate can substitute for endogenous FASN-generated palmitate. Furthermore, BRG1 regulation of proliferation through fatty acid metabolism is breast cancer specific. We showed that key fatty acid synthesis enzymes are not upregulated by BRG1 in non-tumorigenic MCF-10A mammary epithelial cells (59). Though MCF-10A cells also require BRG1 for proliferation (84), this requirement has a different mechanism. Restoration of BRG1 expression in cells depleted for both BRG1 and BRM rescued lipid synthesis, the expression of lipogenic enzymes and cell proliferation so BRM is not required for these effects in this system.

Figure 1
The chromatin remodeling enzyme Brahma-related gene 1 (BRG1) epigenetically regulates key enzymes in de novo fatty acid biosynthesis. The pathway for de novo fatty acid synthesis requires the enzymes ATP citrate lyase (ACLY), acetyl CoA carboxylase (ACC), ...

Targeting BRG1 for Breast Cancer Therapy

Chromatin remodeling complexes have not been viewed as a drugable target until recently, but our work shows that the BRG1 chromatin remodeling enzyme is an especially promising target for epigenetic breast cancer chemotherapy (28, 59, 85). Inhibition of BRG1 function decreases tumor cell proliferation, decreases tumor mass in mouse models, and potentiates tumor cell killing by clinically used chemotherapy drugs.

Only two BRG1 inhibitors have been reported. PFI-3, a Pfizer/Structural Genomics Consortium candidate, is a small molecule inhibitor that specifically targets the bromo domains of BRG1, BRM, and PB1 (86, 87). We treated three triple-negative breast cancer cell lines, MDA-MB-231, MDA-MB-468, and HDQ-P1, with PFI-3 at different doses (85). No inhibition of cell proliferation was observed. This is consistent with recent results demonstrating that PFI-3 does not affect the proliferation rate of other cancer cell lines (87). While PFI-3 does have an effect on some BRG1 functions, it does not dislodge full length BRG1 from chromatin (87) and this may be necessary for inhibiting proliferation through control of lipid synthesis.

The natural product ADAADi (Active DNA-dependent ATPase A Domain inhibitor) inhibits the ATPase activity of the SWI2/SNF2 family of ATPases (88, 89). Enzymes from other families of DNA-dependent ATPases have no or greatly reduced sensitivity to ADAADi, and DNA-independent or RNA-dependent ATPases are not affected (88). ADAADi inhibits BRG1 nucleosome remodeling activity in vitro (88). We tested the ADAADi inhibitor on TNBC cell lines: MDA-MB-231, MDA-MB-468, and HDQ-P1. ADAADiN significantly decreased cell proliferation in these cell lines (85). However, ADAADi failed to decrease cell proliferation significantly in cells with experimentally reduced BRG1 expression. This observation strongly suggests that ADAADiN specifically targeted BRG1 in these cells by interfering with its ATPase function.

ADAADi decreases lipid biosynthesis in breast cancer cells (28) and also sensitizes cells to chemotherapy drugs, just as BRG1 knockdown does (85). After pretreatment with ADAADi, cells were exposed to different doses of six clinically used chemotherapy drugs and cell viability was assayed by MTT. ADAADi significantly increased the drug killing efficacy in MDA-MB-231 and MDA-MB-468 cells from 3-fold to over 10-fold. Therefore, chemical inhibition of the BRG1 ATPase domain targets BRG1-mediated pro-survival pathways in breast cancer cells, decreasing levels of the ABC transporters that pump chemotherapy drugs out of cells and contribute to treatment failure (85).

Metaboloepigenetics

At the level of organisms, food intake affects patterns of gene expression. At the level of cells, levels of nutrients and metabolites regulate patterns of gene expression. Multiple mechanisms have been described and many remain to be discovered (9092). Epigenetic controls are often exerted through covalent modifications of chromatin proteins or through modification of DNA itself. The essential donor groups for these modifications are important metabolic intermediates including Acetyl CoA, S-adenosylmethionine, ATP, and NAD+.

Here, we will concentrate on histone acetylation and metabolism. In one form of epigenetic regulation, histones can be acetylated at multiple positions on their N-terminal tail domains, affecting gene expression at the proximate genes. The extent of histone acetylation at specific sites depends on relative rates of deposition by histone acetyl transferases and removal by Histone Deacetylases (HDACs). The acetyl donor for histone acetylases is acetyl CoA, a metabolite that is produced downstream of glycolysis by the mitochondrial trichloroacetic acid cycle, by the β-oxidation of fatty acids, or by amino acid catabolism. Acetyl CoA is required for both fatty acid and cholesterol synthesis. ACLY generates acetyl CoA from citrate, ATP, and CoA (Figure (Figure1).1). It partitions to both nucleus and cytoplasm, suggesting that nuclear acetyl CoA can be made locally (93) and that nucleocytoplasmic levels change with the metabolic status of cells, for example with glucose levels (94, 95). Knocking down ACLY reduces the acetylation of core histones H2B, H3, and H4 with consequent reductions in the expression proximate genes (93). As we have found ACLY to be transcriptionally regulated by the chromatin remodeling enzyme BRG1 in triple-negative breast cancer cells (28), BRG1-mediated chromatin remodeling may tune the relationship between metabolism and histone acetylation, linking two distinct mechanisms for epigenetic regulation.

Histones can also be acylated with at least eight other species of short chain carboxyl groups: propionyl, butyryl, 2-hydroxyisobutyryl, succinyl, malonyl, glutaryl, crotonyl and β-hydroxybutyryl (94, 96). The levels of these modifications may be controlled by the metabolic pathways producing these carboxyl groups. This may be a mechanism for integrating readouts from these pathways to control patterns of transcription. There is now evidence that histones are acylated with longer chain fatty acids (97). Such a mechanism would directly link fatty acid levels with histone epigenetics.

Many HDACs exist in mammalian cells. Class III HDACs, also known as sirtuins, are nicotinamide adenine dinucleotide (NAD)-dependent deacetylases (98). NAD is a coenzyme carrying electrons between redox reactions in its reduced form NADH. More than 200 metabolic enzymes use NAD+/NADH as a cofactor, most functioning in catabolism. For example, starting with one glucose molecule, two NAD+ molecules are reduced to NADH in glycolysis, at the step catalyzed by glyceraldehyde 3-phosphate dehydrogenase. The highly related NADP+/NADPH performs the same role for enzyme catalyzed anabolic reactions, for example in the de novo synthesis of palmitate by FASN.

As first shown for SIRT2 (99101), a cytoplasmically localized protein, sirtuins have a deacetylation activity requiring NAD+, but not as an electron carrier. Instead, their reactions use NAD+ in equal stoichiometry to the acetyl group and cleave NAD, generating nicotinamide and 2′-O-acetyl-ADP-ribose. Of the seven mammalian sirtuins, SIRT1, SIRT 6, and SIRT 7 are nuclear proteins, enriched in the nucleoplasm, in heterochromatin, and in nucleoli, respectively, and positioned to deacetylate histones and other nuclear proteins (102). SIRT1 efficiently deacetylates p53 (102).

It has been proposed that this unusual use of NAD+ makes these sirtuins sensors of cellular NAD+ levels. Cellular and nuclear NAD+ levels are close enough to the Km of SIRT1 for NAD+ to make this plausible (103). In this view, cellular NAD+ levels would change in response to metabolic fluxes or stresses and cause changes in histone and other nuclear protein acetylation with consequences on gene expression. Conflicts have been noted between this model and early studies on NAD+ levels that showed little response to starvation (92). NAD+ levels do cycle with circadian rhythms (104) and increase with exercise (105). NAD+/NADH ratios decrease in response to elevated glucose levels in C2C12 skeletal muscle cells while in the muscles of fasted mice SIRT1 decreases expression of AMPK targets in control animals and is necessary for their induction after fasting (106). In mouse liver, NAD+ levels are increased by 33% after fasting for 24 h and return to control levels after 24 h after refeeding (107). SIRT1 protein levels were induced after refeeding, showing a second mechanism for SIRT1 activity regulation. The energy sensor AMPK increases cellular NAD+ levels, increasing SIRT1 deacetylation of downstream SIRT1 targets (108). SIRT1 is proposed to activate AMPK creating a feedback loop between SIRT1 and AMPK that controls energy metabolism.

Therapeutic Intervention in Breast Cancer Epigenetics and Metabolism

The reciprocal relationships between metabolism and epigenetic regulation are attractive opportunities for targeted cancer therapy. Multiple drug candidates targeting epigenetic mechanisms are currently in trials for breast cancer. Among those with published promising results are the HDAC inhibitors SAHA (Vorinostat) (109111), entinostat (112), valproate (113), and romidepsin (114). Romidepsin and vorinostat have been FDA approved for treatment of T-cell lymphomas (115, 116). An inhibitor of a DNA methyltransferase, 5-aza-2′-deoxycytidine (5azaC), causes DNA hypomethylation, is FDA approved for treatment of myelodysplastic syndrome (117, 118), and has early promise for breast cancer (119, 120). The great promise of these drugs should drive the search for other epigenetic targets in cancer therapy.

In the work, we have reviewed here, the chromatin remodeling enzyme BRG1 and its breast cancer-specific effects on lipid metabolism are an attractive target for breast cancer therapy. Our work establishes that one part of the anti-cancer mechanism of BRG1-targeted drugs is an effect on fatty acid synthesis decreasing proliferation. Unlike genetic alterations, epigenetic mechanisms are reversible, promising gentler therapies without permanent off-target effects at distant sites.

Author Contributions

JN wrote sections and edited the contributions of the other authors. AI and QW wrote sections and edited the manuscript. All three authors contributed to the published work reviewed in this article.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Funding

This work was supported by NIH grants P01 CA82834, R21 CA185926, and R01 EB014869.

References

1. Warburg O, Posener K, Negelein E. Über den Stoffwechsel der Carcinomzelle. Biochem Z (1924) 152:309–44.
2. Warburg O. On the origin of cancer cells. Science (1956) 123(3191):309–14.10.1126/science.123.3191.309 [PubMed] [Cross Ref]
3. Wise DR, Thompson CB.. Glutamine addiction: a new therapeutic target in cancer. Trends Biochem Sci (2010) 35(8):427–33.10.1016/j.tibs.2010.05.003 [PMC free article] [PubMed] [Cross Ref]
4. Eagle H. Nutrition needs of mammalian cells in tissue culture. Science (1955) 122(3168):501–14.10.1126/science.122.3168.501 [PubMed] [Cross Ref]
5. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell (2011) 144(5):646–74.10.1016/j.cell.2011.02.013 [PubMed] [Cross Ref]
6. Nelson DL, Cox MM. Lehninger Principles of Biochemistry. New York: Worth Publishers; (2000).
7. Frayn KN.. Adipose tissue as a buffer for daily lipid flux. Diabetologia (2002) 45(9):1201–10.10.1007/s00125-002-0873-y [PubMed] [Cross Ref]
8. Cahill GF, Jr, Aoki TT, Ruderman NB. Ketosis. Trans Am Clin Climatol Assoc (1973) 84:184–202. [PubMed]
9. Cahill GF., Jr. Fuel metabolism in starvation. Annu Rev Nutr (2006) 26:1–22.10.1146/annurev.nutr.26.061505.111258 [PubMed] [Cross Ref]
10. Changeux JP. Allosteric interactions interpreted in terms of quaternary structure. Brookhaven Symp Biol (1964) 17:232–49. [PubMed]
11. Monod J.. From enzymatic adaptation to allosteric transitions. Science (1966) 154(3748):475–83.10.1126/science.154.3748.475 [PubMed] [Cross Ref]
12. Stadtman ER. Allosteric regulation of enzyme activity. Adv Enzymol Relat Areas Mol Biol (1966) 28:41–154. [PubMed]
13. Randle PJ. Endocrine control of metabolism. Annu Rev Physiol (1963) 25:291–324.10.1146/annurev.ph.25.030163.001451 [PubMed] [Cross Ref]
14. Krebs EG. Protein kinases. Curr Top Cell Regul (1972) 5:99–133.10.1016/B978-0-12-152805-8.50010-1 [PubMed] [Cross Ref]
15. Hers HG.. The control of glycogen metabolism in the liver. Annu Rev Biochem (1976) 45:167–89.10.1146/annurev.bi.45.070176.001123 [PubMed] [Cross Ref]
16. Hardie DG. AMPK – sensing energy while talking to other signaling pathways. Cell Metab (2014) 20(6):939–52.10.1016/j.cmet.2014.09.013 [PubMed] [Cross Ref]
17. Carling D, Viollet B.. Beyond energy homeostasis: the expanding role of AMP-activated protein kinase in regulating metabolism. Cell Metab (2015) 21(6):799–804.10.1016/j.cmet.2015.05.005 [PubMed] [Cross Ref]
18. Sabatini DM, Erdjument-Bromage H, Lui M, Tempst P, Snyder SH.. RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell (1994) 78(1):35–43.10.1016/0092-8674(94)90570-3 [PubMed] [Cross Ref]
19. Laplante M, Sabatini DM.. mTOR signaling in growth control and disease. Cell (2012) 149(2):274–93.10.1016/j.cell.2012.03.017 [PMC free article] [PubMed] [Cross Ref]
20. Laplante M, Sabatini DM.. An emerging role of mTOR in lipid biosynthesis. Curr Biol (2009) 19(22):R1046–52.10.1016/j.cub.2009.09.058 [PMC free article] [PubMed] [Cross Ref]
21. Porstmann T, Santos CR, Griffiths B, Cully M, Wu M, Leevers S, et al. SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth. Cell Metab (2008) 8(3):224–36.10.1016/j.cmet.2008.07.007 [PMC free article] [PubMed] [Cross Ref]
22. Duvel K, Yecies JL, Menon S, Raman P, Lipovsky AI, Souza AL, et al. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol Cell (2010) 39(2):171–83.10.1016/j.molcel.2010.06.022 [PMC free article] [PubMed] [Cross Ref]
23. Li S, Brown MS, Goldstein JL.. Bifurcation of insulin signaling pathway in rat liver: mTORC1 required for stimulation of lipogenesis, but not inhibition of gluconeogenesis. Proc Natl Acad Sci U S A (2010) 107(8):3441–6.10.1073/pnas.0914798107 [PubMed] [Cross Ref]
24. Peterson TR, Sengupta SS, Harris TE, Carmack AE, Kang SA, Balderas E, et al. mTOR complex 1 regulates lipin 1 localization to control the SREBP pathway. Cell (2011) 146(3):408–20.10.1016/j.cell.2011.06.034 [PMC free article] [PubMed] [Cross Ref]
25. Wang BT, Ducker GS, Barczak AJ, Barbeau R, Erle DJ, Shokat KM.. The mammalian target of rapamycin regulates cholesterol biosynthetic gene expression and exhibits a rapamycin-resistant transcriptional profile. Proc Natl Acad Sci U S A (2011) 108(37):15201–6.10.1073/pnas.1103746108 [PubMed] [Cross Ref]
26. Kim JE, Chen J.. regulation of peroxisome proliferator-activated receptor-gamma activity by mammalian target of rapamycin and amino acids in adipogenesis. Diabetes (2004) 53(11):2748–56.10.2337/diabetes.53.11.2748 [PubMed] [Cross Ref]
27. Zhang HH, Huang J, Duvel K, Boback B, Wu S, Squillace RM, et al. Insulin stimulates adipogenesis through the Akt-TSC2-mTORC1 pathway. PLoS One (2009) 4(7):e6189.10.1371/journal.pone.0006189 [PMC free article] [PubMed] [Cross Ref]
28. Wu Q, Madany P, Dobson JR, Schnabl JM, Sharma S, Smith TC, et al. The BRG1 chromatin remodeling enzyme links cancer cell metabolism and proliferation. Oncotarget (2016) 7:38270–81.10.18632/oncotarget.9505 [PMC free article] [PubMed] [Cross Ref]
29. Teperino R, Lempradl A, Pospisilik JA.. Bridging epigenomics and complex disease: the basics. Cell Mol Life Sci (2013) 70(9):1609–21.10.1007/s00018-013-1299-z [PubMed] [Cross Ref]
30. Wilson BG, Roberts CW.. SWI/SNF nucleosome remodellers and cancer. Nat Rev Cancer (2011) 11(7):481–92.10.1038/nrc3068 [PubMed] [Cross Ref]
31. Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell (2012) 150(1):12–27.10.1016/j.cell.2012.06.013 [PubMed] [Cross Ref]
32. Bowman GD.. Mechanisms of ATP-dependent nucleosome sliding. Curr Opin Struct Biol (2010) 20(1):73–81.10.1016/j.sbi.2009.12.002 [PMC free article] [PubMed] [Cross Ref]
33. Flaus A, Owen-Hughes T.. Mechanisms for ATP-dependent chromatin remodelling: the means to the end. FEBS J (2011) 278(19):3579–95.10.1111/j.1742-4658.2011.08281.x [PMC free article] [PubMed] [Cross Ref]
34. Hota SK, Bartholomew B.. Diversity of operation in ATP-dependent chromatin remodelers. Biochim Biophys Acta (2011) 1809(9):476–87.10.1016/j.bbagrm.2011.05.007 [PMC free article] [PubMed] [Cross Ref]
35. Khavari PA, Peterson CL, Tamkun JW, Mendel DB, Crabtree GR.. BRG1 contains a conserved domain of the SWI2/SNF2 family necessary for normal mitotic growth and transcription. Nature (1993) 366(6451):170–4.10.1038/366170a0 [PubMed] [Cross Ref]
36. Muchardt C, Yaniv M.. A human homologue of Saccharomyces cerevisiae SNF2/SWI2 and Drosophila brm genes potentiates transcriptional activation by the glucocorticoid receptor. EMBO J (1993) 12(11):4279–90. [PubMed]
37. Chiba H, Muramatsu M, Nomoto A, Kato H.. Two human homologues of Saccharomyces cerevisiae SWI2/SNF2 and Drosophila brahma are transcriptional coactivators cooperating with the estrogen receptor and the retinoic acid receptor. Nucleic Acids Res (1994) 22(10):1815–20.10.1093/nar/22.10.1815 [PMC free article] [PubMed] [Cross Ref]
38. Imbalzano AN, Kwon H, Green MR, Kingston RE.. Facilitated binding of TATA-binding protein to nucleosomal DNA. Nature (1994) 370(6489):481–5.10.1038/370481a0 [PubMed] [Cross Ref]
39. Kwon H, Imbalzano AN, Khavari PA, Kingston RE, Green MR.. Nucleosome disruption and enhancement of activator binding by a human SW1/SNF complex. Nature (1994) 370(6489):477–81.10.1038/370477a0 [PubMed] [Cross Ref]
40. Ho L, Crabtree GR.. Chromatin remodelling during development. Nature (2010) 463(7280):474–84.10.1038/nature08911 [PMC free article] [PubMed] [Cross Ref]
41. Hargreaves DC, Crabtree GR.. ATP-dependent chromatin remodeling: genetics, genomics and mechanisms. Cell Res (2011) 21(3):396–420.10.1038/cr.2011.32 [PMC free article] [PubMed] [Cross Ref]
42. Wu JI.. Diverse functions of ATP-dependent chromatin remodeling complexes in development and cancer. Chin J Biochem Biophys (2012) 44(1):54–69.10.1093/abbs/gmr099 [PubMed] [Cross Ref]
43. Papamichos-Chronakis M, Peterson CL.. Chromatin and the genome integrity network. Nat Rev Genet (2013) 14(1):62–75.10.1038/nrg3345 [PMC free article] [PubMed] [Cross Ref]
44. Klochendler-Yeivin A, Fiette L, Barra J, Muchardt C, Babinet C, Yaniv M.. The murine SNF5/INI1 chromatin remodeling factor is essential for embryonic development and tumor suppression. EMBO Rep (2000) 1(6):500–6.10.1093/embo-reports/kvd129 [PubMed] [Cross Ref]
45. Roberts CW, Galusha SA, McMenamin ME, Fletcher CD, Orkin SH.. Haploinsufficiency of Snf5 (integrase interactor 1) predisposes to malignant rhabdoid tumors in mice. Proc Natl Acad Sci U S A (2000) 97(25):13796–800.10.1073/pnas.250492697 [PubMed] [Cross Ref]
46. Guidi CJ, Sands AT, Zambrowicz BP, Turner TK, Demers DA, Webster W, et al. Disruption of Ini1 leads to peri-implantation lethality and tumorigenesis in mice. Mol Cell Biol (2001) 21(10):3598–603.10.1128/MCB.21.10.3598-3603.2001 [PMC free article] [PubMed] [Cross Ref]
47. Medina PP, Romero OA, Kohno T, Montuenga LM, Pio R, Yokota J, et al. Frequent BRG1/SMARCA4-inactivating mutations in human lung cancer cell lines. Hum Mutat (2008) 29(5):617–22.10.1002/humu.20730 [PubMed] [Cross Ref]
48. Wang X, Sansam CG, Thom CS, Metzger D, Evans JA, Nguyen PT, et al. Oncogenesis caused by loss of the SNF5 tumor suppressor is dependent on activity of BRG1, the ATPase of the SWI/SNF chromatin remodeling complex. Cancer Res (2009) 69(20):8094–101.10.1158/0008-5472.CAN-09-0733 [PMC free article] [PubMed] [Cross Ref]
49. Oike T, Ogiwara H, Tominaga Y, Ito K, Ando O, Tsuta K, et al. A synthetic lethality-based strategy to treat cancers harboring a genetic deficiency in the chromatin remodeling factor BRG1. Cancer Res (2013) 73(17):5508–18.10.1158/0008-5472.CAN-12-4593 [PubMed] [Cross Ref]
50. Hoffman GR, Rahal R, Buxton F, Xiang K, McAllister G, Frias E, et al. Functional epigenetics approach identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers. Proc Natl Acad Sci U S A (2014) 111(8):3128–33.10.1073/pnas.1316793111 [PubMed] [Cross Ref]
51. Sentani K, Oue N, Kondo H, Kuraoka K, Motoshita J, Ito R, et al. Increased expression but not genetic alteration of BRG1, a component of the SWI/SNF complex, is associated with the advanced stage of human gastric carcinomas. Pathobiology (2001) 69(6):315–20.10.1159/000064638 [PubMed] [Cross Ref]
52. Sun A, Tawfik O, Gayed B, Thrasher JB, Hoestje S, Li C, et al. Aberrant expression of SWI/SNF catalytic subunits BRG1/BRM is associated with tumor development and increased invasiveness in prostate cancers. Prostate (2007) 67(2):203–13.10.1002/pros.20521 [PubMed] [Cross Ref]
53. Saladi SV, Keenen B, Marathe HG, Qi H, Chin KV, de la Serna IL.. Modulation of extracellular matrix/adhesion molecule expression by BRG1 is associated with increased melanoma invasiveness. Mol Cancer (2010) 9:280.10.1186/1476-4598-9-280 [PMC free article] [PubMed] [Cross Ref]
54. Watanabe T, Semba S, Yokozaki H.. Regulation of PTEN expression by the SWI/SNF chromatin-remodelling protein BRG1 in human colorectal carcinoma cells. Br J Cancer (2011) 104(1):146–54.10.1038/sj.bjc.6606018 [PMC free article] [PubMed] [Cross Ref]
55. Bai J, Mei P, Zhang C, Chen F, Li C, Pan Z, et al. BRG1 is a prognostic marker and potential therapeutic target in human breast cancer. PLoS One (2013) 8(3):e59772.10.1371/journal.pone.0059772 [PMC free article] [PubMed] [Cross Ref]
56. Shi J, Whyte WA, Zepeda-Mendoza CJ, Milazzo JP, Shen C, Roe JS, et al. Role of SWI/SNF in acute leukemia maintenance and enhancer-mediated Myc regulation. Genes Dev (2013) 27(24):2648–62.10.1101/gad.232710.113 [PubMed] [Cross Ref]
57. Liu X, Tian X, Wang F, Ma Y, Kornmann M, Yang Y.. BRG1 promotes chemoresistance of pancreatic cancer cells through crosstalking with Akt signalling. Eur J Cancer (2014) 50(13):2251–62.10.1016/j.ejca.2014.05.017 [PubMed] [Cross Ref]
58. Fillmore CM, Xu C, Desai PT, Berry JM, Rowbotham SP, Lin YJ, et al. EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors. Nature (2015) 520(7546):239–42.10.1038/nature14122 [PMC free article] [PubMed] [Cross Ref]
59. Wu Q, Madany P, Akech J, Dobson JR, Douthwright S, Browne G, et al. The SWI/SNF ATPases are required for triple negative breast cancer cell proliferation. J Cell Physiol (2015) 230:2683–94.10.1002/jcp.24991 [PMC free article] [PubMed] [Cross Ref]
60. Jubierre L, Soriano A, Planells-Ferrer L, Paris-Coderch L, Tenbaum SP, Romero OA, et al. BRG1/SMARCA4 is essential for neuroblastoma cell viability through modulation of cell death and survival pathways. Oncogene (2016) 35(39):5179–90.10.1038/onc.2016.50 [PubMed] [Cross Ref]
61. Bultman S, Gebuhr T, Yee D, La Mantia C, Nicholson J, Gilliam A, et al. A Brg1 null mutation in the mouse reveals functional differences among mammalian SWI/SNF complexes. Mol Cell (2000) 6(6):1287–95.10.1016/S1097-2765(00)00127-1 [PubMed] [Cross Ref]
62. Bultman SJ, Herschkowitz JI, Godfrey V, Gebuhr TC, Yaniv M, Perou CM, et al. Characterization of mammary tumors from Brg1 heterozygous mice. Oncogene (2008) 27(4):460–8.10.1038/sj.onc.1210664 [PubMed] [Cross Ref]
63. Serber DW, Rogala A, Makarem M, Rosson GB, Simin K, Godfrey V, et al. The BRG1 chromatin remodeler protects against ovarian cysts, uterine tumors, and mammary tumors in a lineage-specific manner. PLoS One (2012) 7(2):e31346.10.1371/journal.pone.0031346 [PMC free article] [PubMed] [Cross Ref]
64. Network TCGA.. Comprehensive molecular portraits of human breast tumours. Nature (2012) 490(7418):61–70.10.1038/nature11412 [PMC free article] [PubMed] [Cross Ref]
65. Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer (2007) 7(10):763–77.10.1038/nrc2222 [PubMed] [Cross Ref]
66. Vazquez-Martin A, Colomer R, Brunet J, Lupu R, Menendez JA.. Overexpression of fatty acid synthase gene activates HER1/HER2 tyrosine kinase receptors in human breast epithelial cells. Cell Prolif (2008) 41(1):59–85.10.1111/j.1365-2184.2007.00498.x [PubMed] [Cross Ref]
67. Verhoeven G. [Androgens and increased lipogenesis in prostate cancer. Cell biologic and clinical perspectives]. Verh K Acad Geneeskd Belg (2002) 64(3):189–195; discussion 195–186. [PubMed]
68. Martel PM, Bingham CM, McGraw CJ, Baker CL, Morganelli PM, Meng ML, et al. S14 protein in breast cancer cells: direct evidence of regulation by SREBP-1c, superinduction with progestin, and effects on cell growth. Exp Cell Res (2006) 312(3):278–88.10.1016/j.yexcr.2005.10.022 [PubMed] [Cross Ref]
69. Migita T, Narita T, Nomura K, Miyagi E, Inazuka F, Matsuura M, et al. ATP citrate lyase: activation and therapeutic implications in non-small cell lung cancer. Cancer Res (2008) 68(20):8547–54.10.1158/0008-5472.CAN-08-1235 [PubMed] [Cross Ref]
70. Mukherjee A, Wu J, Barbour S, Fang X.. Lysophosphatidic acid activates lipogenic pathways and de novo lipid synthesis in ovarian cancer cells. J Biol Chem (2012) 287(30):24990–5000.10.1074/jbc.M112.340083 [PMC free article] [PubMed] [Cross Ref]
71. Mashima T, Seimiya H, Tsuruo T.. De novo fatty-acid synthesis and related pathways as molecular targets for cancer therapy. Br J Cancer (2009) 100(9):1369–72.10.1038/sj.bjc.6605007 [PMC free article] [PubMed] [Cross Ref]
72. Kuhajda FP, Jenner K, Wood FD, Hennigar RA, Jacobs LB, Dick JD, et al. Fatty acid synthesis: a potential selective target for antineoplastic therapy. Proc Natl Acad Sci U S A (1994) 91(14):6379–83.10.1073/pnas.91.14.6379 [PubMed] [Cross Ref]
73. Zhou W, Han WF, Landree LE, Thupari JN, Pinn ML, Bililign T, et al. Fatty acid synthase inhibition activates AMP-activated protein kinase in SKOV3 human ovarian cancer cells. Cancer Res (2007) 67(7):2964–71.10.1158/0008-5472.CAN-06-3439 [PubMed] [Cross Ref]
74. Kridel SJ, Axelrod F, Rozenkrantz N, Smith JW.. Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity. Cancer Res (2004) 64(6):2070–5.10.1158/0008-5472.CAN-03-3645 [PubMed] [Cross Ref]
75. Hatzivassiliou G, Zhao F, Bauer DE, Andreadis C, Shaw AN, Dhanak D, et al. ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell (2005) 8(4):311–21.10.1016/j.ccr.2005.09.008 [PubMed] [Cross Ref]
76. Chajes V, Cambot M, Moreau K, Lenoir GM, Joulin V.. Acetyl-CoA carboxylase alpha is essential to breast cancer cell survival. Cancer Res (2006) 66(10):5287–94.10.1158/0008-5472.CAN-05-1489 [PubMed] [Cross Ref]
77. Zaidi N, Swinnen JV, Smans K.. ATP-citrate lyase: a key player in cancer metabolism. Cancer Res (2012) 72(15):3709–14.10.1158/0008-5472.CAN-11-4112 [PubMed] [Cross Ref]
78. Mertins P, Mani DR, Ruggles KV, Gillette MA, Clauser KR, Wang P, et al. Proteogenomics connects somatic mutations to signalling in breast cancer. Nature (2016) 534(7605):55–62.10.1038/nature18003 [PMC free article] [PubMed] [Cross Ref]
79. Kadoch C, Hargreaves DC, Hodges C, Elias L, Ho L, Ranish J, et al. Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy. Nat Genet (2013) 45(6):592–601.10.1038/ng.2628ng.2628 [PMC free article] [PubMed] [Cross Ref]
80. Lin H, Wong RP, Martinka M, Li G.. BRG1 expression is increased in human cutaneous melanoma. Br J Dermatol (2010) 163(3):502–10.10.1111/j.1365-2133.2010.09851.x [PubMed] [Cross Ref]
81. Reisman D, Glaros S, Thompson EA.. The SWI/SNF complex and cancer. Oncogene (2009) 28(14):1653–68.10.1038/onc.2009.4 [PubMed] [Cross Ref]
82. Bourgo RJ, Siddiqui H, Fox S, Solomon D, Sansam CG, Yaniv M, et al. SWI/SNF-deficiency results in aberrant chromatin organization, mitotic failure, and diminished proliferative capacity. Mol Biol Cell (2009) 20(14):3192–9.10.1091/mbc.E08-12-1224 [PMC free article] [PubMed] [Cross Ref]
83. Naidu SR, Love IM, Imbalzano AN, Grossman SR, Androphy EJ.. The SWI/SNF chromatin remodeling subunit BRG1 is a critical regulator of p53 necessary for proliferation of malignant cells. Oncogene (2009) 28(27):2492–501.10.1038/onc.2009.121 [PMC free article] [PubMed] [Cross Ref]
84. Cohet N, Stewart KM, Mudhasani R, Asirvatham AJ, Mallappa C, Imbalzano KM, et al. SWI/SNF chromatin remodeling enzyme ATPases promote cell proliferation in normal mammary epithelial cells. J Cell Physiol (2010) 223(3):667–78.10.1002/jcp.22072 [PMC free article] [PubMed] [Cross Ref]
85. Wu Q, Sharma S, Cui H, LeBlanc SE, Zhang H, Muthuswami R, et al. Targeting the chromatin remodeling enzyme BRG1 increases the efficacy of chemotherapy drugs in breast cancer cells. Oncotarget (2016) 7:27158–75.10.18632/oncotarget.8384 [PMC free article] [PubMed] [Cross Ref]
86. Fedorov O, Castex J, Tallant C, Owen DR, Martin S, Aldeghi M, et al. Selective targeting of the BRG/PB1 bromodomains impairs embryonic and trophoblast stem cell maintenance. Sci Adv (2015) 1(10):e1500723.10.1126/sciadv.1500723 [PMC free article] [PubMed] [Cross Ref]
87. Vangamudi B, Paul TA, Shah PK, Kost-Alimova M, Nottebaum L, Shi X, et al. The SMARCA2/4 ATPase domain surpasses the bromodomain as a drug target in SWI/SNF mutant cancers: insights from cDNA rescue and PFI-3 inhibitor studies. Cancer Res (2015) 75(18):3865–78.10.1158/0008-5472.CAN-14-3798 [PMC free article] [PubMed] [Cross Ref]
88. Muthuswami R, Mesner LD, Wang D, Hill DA, Imbalzano AN, Hockensmith JW.. Phosphoaminoglycosides inhibit SWI2/SNF2 family DNA-dependent molecular motor domains. Biochemistry (2000) 39(15):4358–65.10.1021/bi992503r [PubMed] [Cross Ref]
89. Dutta P, Tanti GK, Sharma S, Goswami SK, Komath SS, Mayo MW, et al. Global epigenetic changes induced by SWI2/SNF2 inhibitors characterize neomycin-resistant mammalian cells. PLoS One (2012) 7(11):e49822.10.1371/journal.pone.0049822 [PMC free article] [PubMed] [Cross Ref]
90. Donohoe DR, Bultman SJ.. Metaboloepigenetics: interrelationships between energy metabolism and epigenetic control of gene expression. J Cell Physiol (2012) 227(9):3169–77.10.1002/jcp.24054 [PMC free article] [PubMed] [Cross Ref]
91. Lu C, Thompson CB.. Metabolic regulation of epigenetics. Cell Metab (2012) 16(1):9–17.10.1016/j.cmet.2012.06.001 [PMC free article] [PubMed] [Cross Ref]
92. Kaelin WG, Jr, McKnight SL. Influence of metabolism on epigenetics and disease. Cell (2013) 153(1):56–69.10.1016/j.cell.2013.03.004 [PMC free article] [PubMed] [Cross Ref]
93. Wellen KE, Hatzivassiliou G, Sachdeva UM, Bui TV, Cross JR, Thompson CB.. ATP-citrate lyase links cellular metabolism to histone acetylation. Science (2009) 324(5930):1076–80.10.1126/science.1164097 [PMC free article] [PubMed] [Cross Ref]
94. Lin H, Su X, He B.. Protein lysine acylation and cysteine succination by intermediates of energy metabolism. ACS Chem Biol (2012) 7(6):947–60.10.1021/cb3001793 [PMC free article] [PubMed] [Cross Ref]
95. Shi L, Tu BP.. Acetyl-CoA and the regulation of metabolism: mechanisms and consequences. Curr Opin Cell Biol (2015) 33:125–31.10.1016/j.ceb.2015.02.003 [PMC free article] [PubMed] [Cross Ref]
96. Sabari BR, Zhang D, Allis CD, Zhao Y. Metabolic regulation of gene expression through histone acylations. Nat Rev Mol Cell Biol (2016) 18:90–101.10.1038/nrm.2016.140 [PMC free article] [PubMed] [Cross Ref]
97. Liu Z, Yang T, Li X, Peng T, Hang HC, Li XD. Integrative chemical biology approaches for identification and characterization of “erasers” for fatty-acid-acylated lysine residues within proteins. Angew Chem Int Ed Engl (2015) 54(4):1149–52.10.1002/anie.201408763 [PMC free article] [PubMed] [Cross Ref]
98. Imai S, Guarente L.. NAD+ and sirtuins in aging and disease. Trends Cell Biol (2014) 24(8):464–71.10.1016/j.tcb.2014.04.002 [PMC free article] [PubMed] [Cross Ref]
99. Imai S, Armstrong CM, Kaeberlein M, Guarente L.. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature (2000) 403(6771):795–800.10.1038/35001622 [PubMed] [Cross Ref]
100. Landry J, Slama JT, Sternglanz R.. Role of NAD(+) in the deacetylase activity of the SIR2-like proteins. Biochem Biophys Res Commun (2000) 278(3):685–90.10.1006/bbrc.2000.3854 [PubMed] [Cross Ref]
101. Smith JS, Brachmann CB, Celic I, Kenna MA, Muhammad S, Starai VJ, et al. A phylogenetically conserved NAD+-dependent protein deacetylase activity in the Sir2 protein family. Proc Natl Acad Sci U S A (2000) 97(12):6658–63.10.1073/pnas.97.12.6658 [PubMed] [Cross Ref]
102. Michishita E, Park JY, Burneskis JM, Barrett JC, Horikawa I.. Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins. Mol Biol Cell (2005) 16(10):4623–35.10.1091/mbc.E05-01-0033 [PMC free article] [PubMed] [Cross Ref]
103. Houtkooper RH, Canto C, Wanders RJ, Auwerx J.. The secret life of NAD+: an old metabolite controlling new metabolic signaling pathways. Endocr Rev (2010) 31(2):194–223.10.1210/er.2009-0026 [PubMed] [Cross Ref]
104. Ramsey KM, Yoshino J, Brace CS, Abrassart D, Kobayashi Y, Marcheva B, et al. Circadian clock feedback cycle through NAMPT-mediated NAD+ biosynthesis. Science (2009) 324(5927):651–4.10.1126/science.1171641 [PMC free article] [PubMed] [Cross Ref]
105. Koltai E, Szabo Z, Atalay M, Boldogh I, Naito H, Goto S, et al. Exercise alters SIRT1, SIRT6, NAD and NAMPT levels in skeletal muscle of aged rats. Mech Ageing Dev (2010) 131(1):21–8.10.1016/j.mad.2009.11.002 [PMC free article] [PubMed] [Cross Ref]
106. Fulco M, Cen Y, Zhao P, Hoffman EP, McBurney MW, Sauve AA, et al. Glucose restriction inhibits skeletal myoblast differentiation by activating SIRT1 through AMPK-mediated regulation of Nampt. Dev Cell (2008) 14(5):661–73.10.1016/j.devcel.2008.02.004 [PMC free article] [PubMed] [Cross Ref]
107. Rodgers JT, Lerin C, Haas W, Gygi SP, Spiegelman BM, Puigserver P.. Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature (2005) 434(7029):113–8.10.1038/nature03354 [PubMed] [Cross Ref]
108. Canto C, Gerhart-Hines Z, Feige JN, Lagouge M, Noriega L, Milne JC, et al. AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature (2009) 458(7241):1056–60.10.1038/nature07813 [PMC free article] [PubMed] [Cross Ref]
109. Luu TH, Morgan RJ, Leong L, Lim D, McNamara M, Portnow J, et al. A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study. Clin Cancer Res (2008) 14(21):7138–42.10.1158/1078-0432.CCR-08-0122 [PMC free article] [PubMed] [Cross Ref]
110. Ramaswamy B, Fiskus W, Cohen B, Pellegrino C, Hershman DL, Chuang E, et al. Phase I-II study of vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer: evidence for vorinostat-induced tubulin acetylation and Hsp90 inhibition in vivo. Breast Cancer Res Treat (2012) 132(3):1063–72.10.1007/s10549-011-1928-x [PMC free article] [PubMed] [Cross Ref]
111. Stearns V, Jacobs LK, Fackler M, Tsangaris TN, Rudek MA, Higgins M, et al. Biomarker modulation following short-term vorinostat in women with newly diagnosed primary breast cancer. Clin Cancer Res (2013) 19(14):4008–16.10.1158/1078-0432.CCR-13-0033 [PMC free article] [PubMed] [Cross Ref]
112. Yardley DA, Ismail-Khan RR, Melichar B, Lichinitser M, Munster PN, Klein PM, et al. Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor. J Clin Oncol (2013) 31(17):2128–35.10.1200/JCO.2012.43.7251 [PMC free article] [PubMed] [Cross Ref]
113. Munster P, Marchion D, Bicaku E, Lacevic M, Kim J, Centeno B, et al. Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC. Clin Cancer Res (2009) 15(7):2488–96.10.1158/1078-0432.CCR-08-1930 [PubMed] [Cross Ref]
114. Robertson FM, Chu K, Boley KM, Ye Z, Liu H, Wright MC, et al. The class I HDAC inhibitor romidepsin targets inflammatory breast cancer tumor emboli and synergizes with paclitaxel to inhibit metastasis. J Exp Ther Oncol (2013) 10(3):219–33. [PubMed]
115. Duvic M, Talpur R, Ni X, Zhang C, Hazarika P, Kelly C, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood (2007) 109(1):31–9.10.1182/blood-2006-06-025999 [PubMed] [Cross Ref]
116. Olsen EA, Kim YH, Kuzel TM, Pacheco TR, Foss FM, Parker S, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol (2007) 25(21):3109–15.10.1200/JCO.2006.10.2434 [PubMed] [Cross Ref]
117. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol (2009) 10(3):223–32.10.1016/S1470-2045(09)70003-8 [PMC free article] [PubMed] [Cross Ref]
118. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Gattermann N, Germing U, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol (2010) 28(4):562–9.10.1200/JCO.2009.23.8329 [PubMed] [Cross Ref]
119. Borges S, Doppler H, Perez EA, Andorfer CA, Sun Z, Anastasiadis PZ, et al. Pharmacologic reversion of epigenetic silencing of the PRKD1 promoter blocks breast tumor cell invasion and metastasis. Breast Cancer Res (2013) 15(2):R66.10.1186/bcr3460 [PMC free article] [PubMed] [Cross Ref]
120. Borges S, Doppler HR, Storz P.. A combination treatment with DNA methyltransferase inhibitors and suramin decreases invasiveness of breast cancer cells. Breast Cancer Res Treat (2014) 144(1):79–91.10.1007/s10549-014-2857-2 [PMC free article] [PubMed] [Cross Ref]

Articles from Frontiers in Oncology are provided here courtesy of Frontiers Media SA